Eris Lifesciences Limited has been penalised ₹4,24,800 each by BSE Limited and the National Stock Exchange of India Limited for non-compliance with board composition norms during the quarter ended March 31, 2026. The fines were imposed via letters dated May 27, 2026, following a violation of Regulation 17(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which mandates specific requirements for the composition of the Board of Directors. The company clarified that the non-compliance occurred due to a board vacancy created by the completion of the term of an Independent Director. This vacancy has since been filled effective March 14, 2026, and the company stated that it is now in compliance with Regulation 17(1) of the SEBI Listing Regulations.

Details of the Penalty

The exchanges imposed the monetary penalty following the review of the company's board structure during the specified period. The company confirmed that there is no material impact on its financial or operational activities beyond the payment of the penalty amounts.

Eris Lifesciences affirmed its commitment to ensuring full compliance with all applicable laws and regulatory requirements moving forward. The disclosure was made in accordance with Regulation 30 of the SEBI Listing Regulations and the relevant SEBI master circular.

Promoters of Eris Lifesciences Limited have confirmed that they hold 7,47,08,744 equity shares, representing approximately 53.92% of the total shareholding as on March 31, 2026. In a declaration submitted to the stock exchanges, the promoters stated that there are no encumbrances on these shares, directly or indirectly, other than those already disclosed during the financial year. This disclosure ensures shareholders that the promoter group's significant stake remains unpledged, providing stability to the company's ownership structure.

The declaration was made by Kaushal Kamlesh Shah on behalf of all Promoters and the Promoter Group pursuant to Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The filing was addressed to BSE Limited and National Stock Exchange of India Limited, as well as the Company Secretary of Eris Lifesciences Limited, to update official records.

Shareholding Details

The disclosure provides specific details regarding the promoter group's holding status for the financial year ended March 31, 2026.

The confirmation of a clean, unencumbered stake is significant for market participants, as it indicates that the promoters have not utilized their shares to raise funds, which could otherwise signal financial stress or liquidity requirements. The document was digitally signed by Kaushal Kamlesh Shah on April 06, 2026.